NYSE American accepts AEON's compliance plan; delisting risk deferred to Aug 2026

AEON Biopharma, Inc.

NYSE American accepted AEON's compliance plan on April 22, 2025, granting until August 3, 2026 to meet listing standards under Sections 1003(a)(i)-(iii).
AEON remains listed on NYSE American under symbol AEON during the Plan Period, subject to periodic progress reviews.
Failure to regain compliance or make sufficient progress by August 3, 2026 may lead to delisting proceedings.
Non-compliance was first disclosed in February 2025; plan submission deadline was March 5, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.